Новости в лекарственном лечении метастатической увеальной меланомы

    1. Назарова В.В. Лечение и прогноз метастатической увеальной меланомы. Автореф. дис. … канд. мед. наук. М.; 2019 [Nazarova VV. Treatment and prognosis of metastatic uveal melanoma [Аbstract of the dissertation]. М.; 2019. (In Russ.)]

    2. Piulats JM, Espinosa E, de la Cruz Merino L, Varela M, Carrion LA, Martin-Algarra S, Castro RL, et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the Spanish multidisciplinary melanoma group (GEM-1402). J Clin Oncol. 2021;39(6): 586–598. doi: 10.1200/ JCO.20.00550

    3. Pelster M, Grushkus SK, Bassett R, Gombos DS, Shephard M, Posada L, Glover M, Diad A, Hwu P, Patel SP. Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM). J Clin Oncol. 2019;37(15): 9522. doi: 10.1200/ JCO.2019.37.15_suppl.9522

    4. Магомедова З.Р., Назарова В.В., Орлова К.В., Унгурян В.М., Демидов Л.В. Лечение метастатической увеальной меланомы: обзор литературы. Вопросы онкологии. 2024;70(4): 606–613. [Magomedova ZR, Nazarova VV, Orlova KV, Unguryan VM, Demidov LV. Treatment of metastatic uveal melanoma: a literature review. Problems of Oncology. 2024;70(4): 606–613. (In Russ.)] doi: 10.37469/0507-3758-2024-70-4- 606-613

    5. Назарова В.В., Орлова К.В., Утяшев И.А. и др. Комбинированная иммунотерапия при метастатической увеальной меланоме. Опыт одного центра. Эффективная фармакотерапия. 2023; 19(16): 64–71. [Nazarova VV, Orlova KV, Utyashev IA, et al. Combined immunotherapy for metastatic uveal melanoma. Single centre experience. Effective Pharmacotherapy. 2023; 19(16): 64–71. (In Russ.)]. doi: 10.33978/2307-3586- 2023-19-16-64-71

    6. Yamada K, Takeuchi M, Fucumoto T, Suzuki M, Kato A, Mizuki Y, Yamada N, Kaneko T, Mizuki N, Horita N. Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis. Sci Rep. 2024;14(7887). doi: 10.1038/s41598-024- 55675-5

    7. Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2018;33(1): 151. doi: 10.1016/j.ccell.2017.12.013

    8. Beigi YZ, Lanjanian H, Fayazi R, Salimi M, Molla Hoseyni BH, Noroozizadeh MH, Masoudi-Nejad A. Heterogeneity and molecular landscape of melanoma: implications for targeted therapy. Mol Biomed. 2024;5(1):17. doi: 10.1186/s43556- 024-00182-2

    9. Sacco JJ, Jackson R, Corrie P, Danson S, Evans TR, Ochsenreither S. et al. A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. Clinical Trial. 2024; 202: 114009. doi: 10.1016/j.ejca.2024.114009

    10. Joshua AM, O’day R, Glasson W, Sia D, McGrath L, Ameratunga M, Cosman R, Psaroulis T. A phase 2 safety and efficacy study of neoadjuvant/adjuvant darovasertib for localized ocular melanoma. J Clin Oncol. 2024;42(16): 9510. doi: 10.1200/ JCO.2024.42.16_suppl.9510

    11. Park JJ, Stewart A, Irvine M, Pedersen S, Ming Z, Carlino MS. et al. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling. Cancer Gene Therapy. 2022;29: 1384–1393. doi: 10.1038/s41417- 022-00457-2

    12. Cao L, Chen S, Sun R, Ashby Jr CR, Wei L, Huang Z, Chen Z-S. Darovasertib, a novel treatment for metastatic uveal melanoma. Front Pharmacol. 2023;28(14): 1232787. doi: 10.3389/fphar.2023.1232787

    13. IDEAYA announces positive interim Phase 2 data for Darovasertib and Crizotinib combination and successful FDA type C meeting on registrational trial design for accelerated approval in first-line metastatic uveal melanoma. News release. IDEAYA Biosciences, Inc. April 23, 2023. Accessed April 25, 2023. Available from: https://prn. to/41y2mK2 [Accessed 10th March 2025]

    14. Liu Xiao-lian, Run-hua Zhou, Pan Jing-xuan, Li Zhi-jie, Yu le, Li Yi-lei. Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations. Pigment Cell & Melanoma Research. 2024;37(3): 411–425. doi: 10.1111/pcmr.13161

    15. Nathan P, Hassel JC, Rutkowski P, Baurain J-F, Butler MO, Schlaak M, et al. Overall survival benefit with Tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13): 1196–1206. doi: 10.1056/NEJMoa2103485

    16. Stenger M. 3-Year overall survival with Tebentafusp in previously untreated advanced uveal melanoma. The ASCO Post. 2023. Available from: https://ascopost.com/ news/november-2023/three-year-overall-survival-with-tebentafusp-in-previouslyuntreated-advanced-uveal-melanoma/ [Accessed 11th March 2025]

    17. Tomsitz D, Ruf T, Heppt M, Staeger R, Ramelyte E, Dummer R. et al. Tebentafusp in patients with metastatic uveal melanoma: A real-life retrospective multicenter study. Cancers. 2023;15(13): 3430. doi: 10.3390/cancers15133430

    18. Dimitriou F, Orloff MM, Koch Hein EC, Cheng PF, Hughes I, Simeone E. Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. Eur J Cancer. 2025;(214): 115161. doi: 10.1016/j.ejca.2024.115161

    19. Di Giacomo AM, Simonelli M, Santangelo F, Amato G, Simonetti E, Graham J, Lahn M, Maio M. J Clin Oncol. Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kd) in patients with metastatic uveal melanoma. 2024;42(16). doi: 10.1200/JCO.2024.42.16_suppl.9597